Search

Your search keyword '"Yasushi Hamaya"' showing total 2 results
Start Over Author "Yasushi Hamaya" Journal bmc cancer
2 results on '"Yasushi Hamaya"'

1. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Author

Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Takahiro Uotani, Shinya Tani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Satoshi Baba, Haruhiko Sugimura, Junko Murai, Yves Pommier, and Takahisa Furuta

Subjects
SLFN11, Esophageal cancer, Chemoradiotherapy, Biomarker, Nedaplatin, DNA damage, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value of SLFN11 expression in esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (dCRT), including the platinum derivative nedaplatin. Methods Seventy-three patients with ESCC who received dCRT were examined. SLFN11 expression was analyzed in pre-dCRT biopsies using immunohistochemistry and evaluated using a histo-score (H-score). Correlation between the H-score and overall survival was analyzed. An H-score ≥ 51 was provisionally defined as indicating high SLFN11 expression. Viability assays were performed using previously established isogenic human cell lines differentially expressing SLFN11 to test the usefulness of SLFN11 as marker of response to the dCRT regimen. Results High SLFN11 expression was independently associated with better prognosis in ESCC patients (hazard ratio = 0.295, 95% CI = 0.143–0.605, p = 0.001 for multivariate analysis). Kaplan-Meier survival curves showed that the prognostic value of high SLFN11 expression was most evident in patients at clinical stages II and III (p = 0.004). In in vitro study, SLFN11-proficient cells were highly sensitive to platinum derivatives compared to SLFN11-deficient cells. Conclusion SLFN11 expression is an independent prognostic factor for ESCC patients treated with dCRT and a potential biomarker for treatment selection of ESCC. Examination of SLFN11 may be particularly useful for clinical Stage II–III patients who wish to choose dCRT (instead of surgery) to preserve esophageal function.

Published
2020
Full Text
View/download PDF

2. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma

Author

Tomohiro Terai, Satoshi Osawa, Masafumi Nishino, Shigeru Kanaoka, Takanori Yamada, Moriya Iwaizumi, Takashi Kosugi, Kosuke Takagaki, Ken Sugimoto, Takahisa Furuta, Ken-ichi Yoshida, Mutsuhiro Ikuma, Mihoko Yamade, Yasushi Hamaya, Yasuhiro Takayanagi, and Chise Kodaira

Subjects
Male, medicine.medical_specialty, Cancer Research, Esophageal Neoplasms, Organoplatinum Compounds, medicine.medical_treatment, Kaplan-Meier Estimate, Gastroenterology, lcsh:RC254-282, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Genetics, Humans, Nedaplatin, Aged, Neoplasm Staging, Aged, 80 and over, Chemotherapy, Leukopenia, Radiotherapy, business.industry, Esophageal cancer, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Combined Modality Therapy, Surgery, Regimen, Treatment Outcome, chemistry, Oncology, Carcinoma, Squamous Cell, Female, Fluorouracil, medicine.symptom, business, Chemoradiotherapy, Progressive disease, Research Article
Abstract

Background Protracted low-dose concurrent chemotherapy combined with radiation has been proposed for enhanced treatment results for esophageal cancer. We evaluated the efficacy and the toxicity of a novel regimen of daily low-dose nedaplatin (cis-diammine-glycolatoplatinum) and continuous infusion of 5-fluorouracil (5-FU) with radiation in patients with esophageal squamous cell carcinoma. Methods Between January 2003 and June 2008, 33 patients with clinical stage I to IVB esophageal squamous cell carcinoma were enrolled. Nedaplatin (10 mg/body/day) was administered daily and 5-FU (500 mg/body/day) was administered continuously for 20 days. Fractionated radiotherapy for a total dose of 50.4-66 Gy was administered together with chemotherapy. Additional chemotherapy with nedaplatin and 5-FU was optionally performed for a maximum of 5 courses after chemoradiotherapy. The primary end-point of this study was to evaluate the tumor response, and the secondary end-points were to evaluate the toxicity and the overall survival. Results Twenty-two patients (72.7%) completed the regimen of chemoradiotherapy. Twenty patients (60.6%) achieved a complete response, 10 patients (30.3%) a partial response. One patient (3.0%) had a stable disease, and 2 (6.1%) a progressive disease. The overall response rate was 90.9% (95% confidence interval: 75.7%-98.1%). For grade 3-4 toxicity, leukopenia was observed in 75.8% of the cases, thrombocytopenia in 24.2%, anemia in 9.1%, and esophagitis in 36.4%, while late grade 3-4 cardiac toxicity occurred in 6.1%. Additional chemotherapy was performed for 26 patients (78.8%) and the median number of courses was 3 (range, 1-5). The 1-, 2- and 3-year survival rates were 83.9%, 76.0% and 58.8%, respectively. The 1- and 2-year survival rates were 94.7% and 88.4% in patients with T1-3 M0 disease, and 66.2% and 55.2% in patients with T4/M1 disease. Conclusion The treatment used in our study may yield a high complete response rate and better survival for each stage of esophageal squamous cell carcinoma. Trial registration ClinicalTrials.gov Identifier: NCT00197444

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results